Pandit, R. , Singh, P. and Kumar, V. (2015) Natural Remedies against Multi-Drug Resistant Mycobacterium tuberculosis. Journal of Tuberculosis Research, 3, 171-183. doi: 10.4236/jtr.2015.34024.
Received 3 November 2015; accepted 18 December 2015; published 22 December 2015
Tuberculosis (TB), caused by Mycobacterium tuberculosis is an infectious deadly disease and the treatment of which is one of the most severe challenges at the global level. Currently more than 20 chemical medications are described for the treatment of TB. Regardless of availability of several drugs to treat TB, the causative agent, M. tuberculosis is nowadays getting resistant toward the conventional drugs and leading to conditions known as Multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). This situation has terrified the global health community and raised a demand for new anti-tuberculosis drugs. Medicinal plants have been used to cure different common as well as lethal diseases by ancient civilizations due to its virtue of variety of chemical compounds which may have some important remedial properties. The aim of the present review is to focus the anti-tubercular medicinal plants native to India as well as the plants effective against MDR or XDR-TB across the globe. In the present review, we have addressed 25 medicinal plants for TB and 16 plants effective against MDR-TB testified from India and 23 herbal plants described for MDR-TB across the world during 2011-2015. These herbal plants can serve as promising candidates for developing novel medications to combat multi-drug resistant M. tuberculosis.
Drug Resistant, Mycobacterium tuberculosis, Medicinal Plants, MDR or XDR-TB
Tuberculosis (TB), an infectious deadly disease caused by the various species of Mycobacterium, especially Mycobacterium tuberculosis, was emerged from East Africa more than three million years ago  .
According to World Health Organization (WHO), TB is the second most fatal disease after HIV, accountable for human death across the globe and about one third of human population is estimated to be infected with M. tuberculosis. However, it is not necessary that all infected person may get the tuberculosis. The carrier stage is called latent tuberculosis, in which M. tuberculosis infected person does not show any symptoms of disease. Still, about 5% to 10% of the infected people have a chance to develop TB, depending upon the immunity of the individual. Around 6.1 million TB patients have been reported in year 2013, of these, about 5.7 million (93%) cases were new. About 9 million people were reported ill due to TB in 2013, of which approximately 1.5 million died due to the disease (Figure 1)  . The disease is highly progressive in Asia and Africa and more than 80% of all TB cases were reported from these two continents  . When we talk about Indian scenario, one report said that TB was reported about 3300 years ago  while according to ancient literature  TB have been reported since 1500BC. Treatment of TB is one of the most severe challenges at the global level. Presently, there are more than 20 drugs which are described for the treatment of TB  among them. Isoniazid, rifampin, ethambutol, pyrazinamide and streptomycin are most commonly used.
However, recent few years have revealed that the causative agent of Tuberculosis, M. tuberculosis is getting resistant towards conventional drugs used for treatment. The development of drug-resistant in M. tuberculosis has frightened the global health community   . Multidrug-resistant tuberculosis (MDR-TB) is a condition where the M. tuberculosis strain is resistant to two most frequently used drugs i.e. first-line oral (Table 1) specifically isoniazid, rifampicin and it was first developed in USA during 1990s   . The improper use of antimicrobial drugs, early treatment cessation, genetic mutation in M. tuberculosis, an inadequate administered treatment, etc. may cause drug resistance   which can then be transmitted to other people in the community. Among all, genetic mutation is the most important cause for the MDR-TB and 7 hotspots loci have been identified across the chromosome which includes RNA polymerase beta subunit gene, rpoB (rifampicin), nicotinamidase, pncA (pyrazinamide), catalase-peroxidase gene, katG (isoniazid); inhibin alpha, mabA(fabG1)-inhA (isoniazid), DNA gyrase subunit A&B (quinolone), and 16S rRNA gene, rrs (streptomycin)   . According to WHO, around 480,000 cases of MDR-TB were reported in 2013-14 and between 20% to 30% of the new cases were from Soviet Union countries. MDR-TB treatment requires the use of second-line drugs (SLDs), which are less effective  and highly expensive compared to first-line drugs  . Other drugs which are recommended for TB treatment includes sulfamethoxazole and mefloquine, however, both the drugs require further validation  . Recently two new anti-TB drugs, bedaquiline which affects the proton pump for ATP synthase and delamanid which blocks the synthesis of mycolic acids have been approved by the US Food and Drug Administration and European Medicines Agency   . Together with MDR-TB, XDR-TB (extensively drug resistant tuberculosis) has also been described where M. tuberculosis is resistant to at least four of the core anti-
Figure 1. Percentage of new TB cases with MDT-TB in 2013-2014  .
Table 1. First and second line recommended by WHO  .
TB drugs including, isoniazid, rifampicin and any of the fluoroquinolones and to one of the three injectable second line drugs (Table 1). Nowadays completely drug?resistant Mycobacterium tuberculosis strains have also been evolved which are resistant to all the first and second line drugs used for TB treatment  –  . Types of report have directed attention of researchers worldwide to find a novel potent drug molecule for the treatment of TB. Recently,  researchers have reviewed new drugs for tuberculosis including PA-824 (Nitroimidazole), Linezolid (Oxazolidinones), Sutezolid (Oxazolidinones), AZD5847 (Oxazolidinones) and SQ109 (1,2-diamine). Most of these drugs are under the clinical trial phase II. Therefore, there is an urgent demand to find out some potential anti-tuberculosis medicines which are effective against the resistant deadly strains. As usual, the “hope for the best” is the natural system and generally mankind is always looking into actinomycetes  –  , fungi   , cyanobactria  and plants   for the new drug molecules. Various drugs have already been identified and still being identified from the natural resources by the mankind.
Further, the interest in herbal medications is due to adverse effect of chemical based anti-TB drugs on the patients, who generally have to administer the drug for longer durations. The adverse effects of first-line oral and second line drugs are summarized in the Table 2. According to one survey in India, the adverse drug reactions during MDR-TB treatment ranges from 57.14% to 94.3% and the most common adversarial effect was found to be gastrointestinal problems (71.7%)  . In contrast to this, herbal medicines are naturally occurring chemical compounds which can be administrated in the form of whole plant or it particular part. The advantages of herbal medications are fewer side effects, affectivity in multiple diseases as they are crude mixture of many plant compounds and are low cost.
The significance of plants has been recognized and documented since ancient time due to virtue of its variety of chemical compounds, which may have some important medicinal properties that can be used to cure diverse diseases. Medicinal plants have been widely used as preventives and curative solutions against different common as well as lethal diseases by ancient cultures. There are some prehistoric data available, in which recipes for medicine preparation from the plants have been discussed  –  . The World Health Organization (WHO) estimated that about 80 percent of world’s population still relied on traditional medicinal plants for their primary health care. The uses of herbs and herbal products have been broadly being accepted in our modern way of life. Moreover  , the majority of new drugs introduced in the United States are derived primarily from the plants. As discussed, most of the chemical drugs cause adverse effects and are costlier, therefore, nowadays there is an increasing inclinations towards the use of an alternative source of medicine, especially based on medicinal plants  . A number of medicinal plants have been reported for anti-mycobacterial activity across the globe  –  .
Ayurveda, means the science of life (Ayur = Life, Veda = Science), is an ancient medical knowledge which was developed in India thousands of years ago and describes numerous plants to treat several diseases. When we particularly talk about TB, more than 250 medicinal plants from India have been reported   . The comprehensive safety, toxicity and clinical studies are needed for these plants before using them effectively as curative and/or preventive medications against TB. Table 3 summarizes the Indian plants reported for anti-mycoba- cterial activity during last 5 (2011-2015) years.
The above data shows that some plants and/or their fractions have very low MIC value (>25 µg/mL) (Table 2) and are effective. These plants are promising candidates to find novel medication for the treatment of TB. However, the emergence of MDR and XDR-TB has further inspired the scientific community to find novel and more potent anti-mycobacterial drug molecules. Various plants across the globe possess anti-mycobacterial activity against MDR-TB  –  . Table 4 summarizes the medicinal plants having anti-mycobacterial activity against MDR-TB reported during 2011-2015 in countries other than India.
India is also one of the leading countries in herbal medicines and researchers are continuously engaged in searching novel drug molecules to combat MDR/XDR-TB. Since last few years several plants have been reported for their anti-mycobacterial activity from India (Table 5).
The review suggests that many plants either confined to India or elsewhere have the unique capability to counter the deadly tuberculosis pathogen. Some plants showed very low MIC values against the clinical isolates of MDR-M. tuberculosis and few of them were also found effective against XDR-TB. These plants surely must be chosen for further researches and attempts should be made to translate this knowledge into some potential anti-TB therapies, either curative or preventive. In some cases the active molecule(s) need to be identified and where the molecule has been identified one should go for generation of safety, efficacy, pharmacokinetics, stability, etc. data through approved clinical experiments, which are essential for drug development, regulatory approval and commercialization. In few studies, it was also observed that most of the data required by the regulatory authorities are available and if some more efforts are made to find out evidences of safety, stability, etc. then these herbal leads may be converted into an alternative and novel solutions to combat MDR and XDR-TB in future.
Authors are grateful to Prof. Anil Gupta, Executive Vice Chair, National Innovation Foundation India for his
honorary guidance and encouragement for carrying out research activities.
RameshPandit,Pawan KumarSingh,VipinKumar, (2015) Natural Remedies against Multi-Drug ResistantMycobacterium tuberculosis. Journal of Tuberculosis Research,03,171-183. doi: 10.4236/jtr.2015.34024
- 2. (2014) Organization WH Global Tuberculosis Report 2014. World Health Organization, Geneva.
- 4. Brothwell, D. and Sandison, A.T. (1967) Diseases in Antiquity. A Survey of the Diseases, Injuries and Surgery of Early Populations. Diseases in Antiquity a Survey of the Diseases, Injuries and Surgery of Early Populations.
- 7. WHO (2014) Global Tuberculosis Report 2014. World Health Organization, Geneva.
- 9. Control, CfD. and Prevention (2006) Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second- Line Drugs—Worldwide, 2000-2004. MMWR Morbidity and Mortality Weekly Report, 55, 301.
- 11. Edlin, B.R., Tokars, J.I., Grieco, M.H., Crawford, J.T., Williams, J., et al. (1992) An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 326, 1514-1521.http://dx.doi.org/10.1056/NEJM199206043262302
- 12. Sharma, S. and Mohan, A. (2004) Multidrug-Resistant Tuberculosis. Indian Journal of Medical Research, 120, 354- 376.
- 14. Ohno, H., Koga, H. and Kohno, S. (1998) Multidrug-Resistant Tuberculosis. 2. Mechanisms of Drug-Resistance in Mycobacterium tuberculosis—Genetic Mechanisms of Drug-Resistance. Kekkaku: [Tuberculosis], 73, 657-663.
- 20. Migliori, G., De Iaco, G., Besozzi, G., Centis, R. and Cirillo, D. (2007) First Tuberculosis Cases in Italy Resistant to All Tested Drugs. Euro Surveillance, 12, Article ID: E070517.
- 24. Mahajan, G.B. and Balachandran, L. (2011) Antibacterial Agents from Actinomycetes—A Review. Frontiers in Bioscience (Elite Edition), 4, 240-253.
- 25. Adegboye, M. and Babalola, O. (2013) Actinomycetes: A Yet Inexhaustive Source of Bioactive Secondary Metabolites. In: Mendez-Vilas, A., Ed., Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, Formatex, Badajoz, 786-795.
- 30. Abdallah, E.M. (2011) Plants: An Alternative Source for Antimicrobials. Journal of Applied Pharmaceutilcal Science, 1, 16-20.
- 31. Katiyar, C., Gupta, A., Kanjilal, S. and Katiyar, S. (2012) Drug Discovery from Plant Sources: An Integrated Approach. Ayu, 33, 10-19.
- 35. Glesinger, L. (1954) Medicine through Centuries. Zora, Zagreb, 21-38.
- 36. Bottcher, H. (1965) Miracle Drugs. Zora, Zagreb, 23-139.
- 37. Castiglioni, A., Krumbhaar, E.B. and Alfred, A. (1947) A History of Medicine. Knopf, New York.
- 40. Santhosh, R.S. and Suriyanarayanan, B. (2014) Plants: A Source for New Antimycobacterial Drugs. Planta Medica, 80, 9-21.
- 41. Newton, S.M., Lau, C. and Wright, C.W. (2000) A Review of Antimycobacterial Natural Products. Phytotherapy Research, 14, 303-322. http://dx.doi.org/10.1002/1099-1573(200008)14:5<303::AID-PTR712>3.0.CO;2-N
- 43. Babalola, I.T., Adelakun, E.A., Wang, Y. and Shode, F.O. (2012) Anti-TB Activity of Sterculia setigera Del., Leaves (Sterculiaceae). Journal of Pharmacognosy and Phytochemistry, 1, 19-26.
- 44. Robles-Zepeda, R.E., Coronado-Aceves, E.W., Velázquez-Contreras, C.A., Ruiz-Bustos, E., Navarro-Navarro, M., et al. (2013) In Vitro Anti-Mycobacterial Activity of Nine Medicinal Plants Used by Ethnic Groups in Sonora, Mexico. BMC Complementary and Alternative Medicine, 13, 329.http://dx.doi.org/10.1186/1472-6882-13-329
- 45. Balcha, E., Mengiste, B., Gebrelibanos, M., Worku, A. and Ameni, G. (2014) Evaluation of In-Vitro Anti-Mycobacterial Activity of Selected Medicinal Plants in Mekelle, Ethiopia. World Applied Sciences Journal, 31, 1217-1220.
- 46. Njeru, S.N., Obonyo, M.A., Ngari, S.M., Nyambati, S., Onsarigo, J.M.N., et al. (2015) Antituberculous, Antimicrobial, Cytotoxicity and Phytochemical Activity Study of Piliostigma thonningii Extract Fractions. Journal of Medicinal Plants Research, 9, 655-663.
- 48. Arya, V. (2011) A Review on Anti-Tubercular Plants. International Journal of PharmaTech Research, 3, 872-880.
- 50. Gupta, V., Shukla, C., Bisht, G., Saikia, D., Kumar, S., et al. (2011) Detection of Anti-Tuberculosis Activity in Some Folklore Plants by Radiometric BACTEC Assay. Letters in Applied Microbiology, 52, 33-40. http://dx.doi.org/10.1111/j.1472-765X.2010.02963.x
- 52. Adaikkappan, P., Kannapiran, M. and Anthonisamy, A. (2012) Anti-Mycobacterial Activity of Withania somnifera and Pueraria tuberosa against Mycobacterium tuberculosis H37Rv. Journal of Academia and Industrial Research, 1, 153- 156.
- 53. Birdi, T., D’souza, D., Tolani, M., Daswani, P., Nair, V., et al. (2012) Assessment of the Activity of Selected Indian Medicinal Plants against Mycobacterium tuberculosis: A Preliminary Screening Using the Microplate Alamar Blue Assay. European Journal of Medicinal Plants, 2, 308-323.http://dx.doi.org/10.9734/EJMP/2012/1638
- 54. Antony, M., James, J., Misra, C.S., Sagadevan, L., Veettil, A.T., et al. (2012) Anti Mycobacterial Activity of the Plant Extracts of Alstonia scholaris. International Journal of Current Pharmaceutical Research, 4, 40-42.
- 58. Viswanathan, V., Phadatare, A. and Mukne, A. (2014) Antimycobacterial and Antibacterial Activity of Allium sativum Bulbs. Indian Journal of Pharmaceutical Sciences, 76, 256-261.
- 59. Rajiniraja, M. and Jayaraman, G. (2014) Bioautography Guided Screening of Selected Indian Medicinal Plants Reveals Potent Antimycobacterial Activity of Allium sativum Extracts-Implication of Non-Sulfur Compounds in Inhibition. International Journal of Pharmacy and Pharmaceutical Sciences, 6, 671-676.
- 60. Munna, S., Basha, S.C., Reddy, P.R., Pramod, N., Kumar, Y.P., et al. (2014) Antitubercular Activity of Actiniopteris radiata Linn. Journal of Global Trends in Pharmaceutical Sciences, 5, 1443-1445.
- 61. Kaur, R. and Kaur, H. (2015) Antitubercular Activity and Phytochemical Screening of Selected Medicinal Plants. Oriental Journal of Chemistry, 31, 597-600.
- 62. Suhitha, S., Devi, S.K., Gunasekaran, K., Carehome Pakyntein, H., Bhattacharjee, A., et al. (2015) Phytochemical Analyses and Activity of Herbal Medicinal Plants of North-East India for Anti-Diabetic, Anti-Cancer and Anti- Tuberculosis and Their Docking Studies. Current Topics in Medicinal Chemistry, 15, 21-36. http://dx.doi.org/10.2174/1568026615666150112104344
- 63. Sheeba, D.G., Gomathi, K.S. and Citarasu, D. (2015) Anti-Mycobacterial and Phytochemical Investigation of Methanol Extracts of Few Medicinal Plants. Journal of Chemical and Pharmaceutical Sciences, 8, 480-486.
- 65. Channabasappa, H.S., Shrinivas, J.D. and Venkatrao, K.H. (2015) Evaluation of Antibacterial and Antitubercular Activity of Cassia fistula Linn Root. International Journal of Research in Pharmaceutical Sciences, 6, 82-84.
- 66. Gaur, R., Thakur, J.P., Yadav, D.K., Kapkoti, D.S., Verma, R.K., et al. (2015) Synthesis, Antitubercular Activity, and Molecular Modeling Studies of Analogues of Isoliquiritigenin and Liquiritigenin, Bioactive Components from Glycyrrhiza glabra. Medicinal Chemistry Research, 24, 3494-3503. http://dx.doi.org/10.1007/s00044-015-1401-1
- 67. Sureram, S., Senadeera, S.P., Hongmanee, P., Mahidol, C., Ruchirawat, S., et al. (2012) Antimycobacterial Activity of Bisbenzylisoquinoline Alkaloids from Tiliacora triandra against Multidrug-Resistant Isolates of Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters, 22, 2902-2905. http://dx.doi.org/10.1016/j.bmcl.2012.02.053
- 68. Leitão, F., Leitão, S.G., de Almeida, M.Z., Cantos, J., Coelho, T., et al. (2013) Medicinal Plants from Open-Air Markets in the State of Rio de Janeiro, Brazil as a Potential Source of New Antimycobacterial Agents. Journal of Ethnopharmacology, 149, 513-521.http://dx.doi.org/10.1016/j.jep.2013.07.009
- 72. Torres-Romero, D., Jimenez, I.A., Rojas, R., Gilman, R.H., Lopez, M., et al. (2011) Dihydro-Beta-Agarofuran Sesquiterpenes Isolated from Celastrus vulcanicola as Potential Anti-Mycobacterium tuberculosis Multidrug-Resistant Agents. Bioorganic & Medicinal Chemistry, 19, 2182-2189.http://dx.doi.org/10.1016/j.bmc.2011.02.034
- 73. Molina-Salinas, G.M., Pena-Rodriguez, L.M., Mata-Cardenas, B.D., Escalante-Erosa, F., Gonzalez-Hernandez, S., et al. (2011) Flourensia cernua: Hexane Extracts a Very Active Mycobactericidal Fraction from an Inactive Leaf Decoction against Pansensitive and Panresistant Mycobacterium tuberculosis. Evidence-Based Complementary and Alternative Medicine: eCAM, 2011, Article ID: 782503.
- 74. Hannan, A., Ikram Ullah, M., Usman, M., Hussain, S., Absar, M., et al. (2011) Anti-Mycobacterial Activity of Garlic (Allium sativum) against Multi-Drug Resistant and Non-Multi-Drug Resistant Mycobacterium tuberculosis. Pakistan Journal of Pharmaceutical Sciences, 24, 81-85.
- 75. Dini, C., Fabbri, A. and Geraci, A. (2011) The Potential Role of Garlic (Allium sativum) against the Multi-Drug Resistant Tuberculosis Pandemic: A Review. Annali dell’Istituto Superiore di Sanita, 47, 465-473.
- 78. Serkani, J.E., Isfahani, B.N., Safaei, H.G., Kermanshahi, R.K. and Asghari, G. (2012) Evaluation of the Effect of Humulus lupulus Alcoholic Extract on Rifampin-Sensitive and Resistant Isolates of Mycobacterium tuberculosis. Research in Pharmaceutical Sciences, 7, 235-242.
- 79. Crandall, P.G., Ricke, S.C., O’Bryan, C.A. and Parrish, N.M. (2012) In Vitro Effects of Citrus Oils against Mycobacterium tuberculosis and Non-Tuberculous Mycobacteria of Clinical Importance. Journal of Environmental Science and Health Part B, Pesticides, Food Contaminants, and Agricultural Wastes, 47, 736-741. http://dx.doi.org/10.1080/03601234.2012.669331
- 80. Leon-Diaz, R., Meckes-Fischer, M., Valdovinos-Martinez, L., Campos, M.G., Hernandez-Pando, R., et al. (2013) Antitubercular Activity and the Subacute Toxicity of (-)-Licarin A in BALB/c Mice: A Neolignan Isolated from Aristolochia taliscana. Archives of Medical Research, 44, 99-104.http://dx.doi.org/10.1016/j.arcmed.2012.12.006
- 82. Jimenez-Arellanes, A., Luna-Herrera, J., Cornejo-Garrido, J., Lopez-Garcia, S., Castro-Mussot, M.E., et al. (2013) Ursolic and Oleanolic Acids as Antimicrobial and Immunomodulatory Compounds for Tuberculosis Treatment. BMC Complementory and Alternative Medicines, 13, 258.http://dx.doi.org/10.1186/1472-6882-13-258
- 83. Uc-Cachon, A.H., Borges-Argaez, R., Said-Fernandez, S., Vargas-Villarreal, J., Gonzalez-Salazar, F., et al. (2014) Naphthoquinones Isolated from Diospyros anisandra Exhibit Potent Activity against Pan-Resistant First-Line Drugs Mycobacterium tuberculosis Strains. Pulmonary Pharmacology and Therapeutics, 27, 114-120. http://dx.doi.org/10.1016/j.pupt.2013.08.001
- 84. Zhang, L., Li, R., Li, M., Qi, Z. and Tian, J. (2015) In Vitro and in Vivo Study of Anti-Tuberculosis Effect of Extracts Isolated from Ranunculi Ternati Radix. Sarcoidosis Vasculitis and Diffuse Lung Diseases. Official Journal of WASOG/ World Association of Sarcoidosis and Other Granulomatous Disorders, 31, 336-342.
- 85. Radji, M., Kurniati, M. and Kiranasari, A. (2015) Comparative Antimycobacterial Activity of Some Indonesian Medicinal Plants against Multi-Drug Resistant Mycobacterium tuberculosis. Journal of Applied Pharmaceutical Science, 5, 19-22.
- 86. Jang, W.S., Jyoti, M.A., Kim, S., Nam, K.W., Ha, T.K., et al. (2015) In Vitro Antituberculosis Activity of Diterpenoids from the Vietnamese Medicinal Plant Croton tonkinensis. Journal of Natural Medicines, 70, 127-132.
- 87. Gupta, R., Thakur, B., Singh, P., Singh, H., Sharma, V., et al. (2010) Anti-Tuberculosis Activity of Selected Medicinal Plants against Multi-Drug Resistant Mycobacterium tuberculosis Isolates. Indian Journal of Medical Research, 131, 809-813.
- 88. Lakshmanan, D., Werngren, J., Jose, L., Suja, K., Nair, M.S., et al. (2011) Ethyl p-Methoxycinnamate Isolated from a Traditional Anti-Tuberculosis Medicinal Herb Inhibits Drug Resistant Strains of Mycobacterium tuberculosis in Vitro. Fitoterapia, 82, 757-761.http://dx.doi.org/10.1016/j.fitote.2011.03.006
- 90. Singh, R., Hussain, S., Verma, R. and Sharma, P. (2013) Anti-Mycobacterial Screening of Five Indian Medicinal Plants and Partial Purification of Active Extracts of Cassia sophera and Urtica dioica. Asian Pacific Journal of Tropical Medicine, 6, 366-371. http://dx.doi.org/10.1016/S1995-7645(13)60040-1
- 92. Basu, S., Ghosh, A. and Hazra, B. (2005) Evaluation of the Antibacterial Activity of Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn.: Isolation of Emodin and Physcion as Active Antibacterial Agents. Phytotherapy Research, 19, 888-894.http://dx.doi.org/10.1002/ptr.1752
- 94. Hazra, B., Sarkar, R., Bhattacharyya, S., Ghosh, P.K., Chel, G., et al. (2002) Synthesis of Plumbagin Derivatives and Their Inhibitory Activities against Ehrlich ascites Carcinoma in Vivo and Leishmania donovani Promastigotes in Vitro. Phytotherapy Research, 16, 133-137.http://dx.doi.org/10.1002/ptr.867
- 95. Prabu, A., Hassan, S., Prabuseenivasan Shainaba, A.S., Hanna, L.E., et al. (2015) Andrographolide: A Potent Antituberculosis Compound That Targets Aminoglycoside 2’-N-Acetyltransferase in Mycobacterium tuberculosis. Journal of Molecular Graphics & Modelling, 61, 133-140. http://dx.doi.org/10.1016/j.jmgm.2015.07.001